873078-93-4

Basic information

• Product Name: N,N-Dimethyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethanamine
• Synonyms: 4-(2-(Dimethylamino)ethoxy)phenylboronic acid, pinacol ester;N,N-Dimethyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethanamine;N,N-Dimethyl-2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]ethylamine, 2-{4-[2-(Dimethylamino)ethoxy]phenyl}-4,4,5,5-tetramethyl-1,3,2-dioxaborolane;4-[2-(Dimethylamino)ethoxy]benzeneboronicacid,pinacolester98%;4-[2-(Dimethylamino)ethoxy]benzeneboronic acid
• CAS NO: 873078-93-4
• Molecular Formula: C₁₆H₂₆BNO₃
• Molecular Weight: 291.2
• Product Categories: blocks;BoronicAcids
• Mol File: 873078-93-4.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: N,N-Dimethyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethanamine(CAS DataBase Reference)
• NIST Chemistry Reference: N,N-Dimethyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethanamine(873078-93-4)
• EPA Substance Registry System: N,N-Dimethyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethanamine(873078-93-4)

Safety Data

• Hazardous Substances Data: 873078-93-4(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
N,N-Dimethyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethanamine is used as a reagent in organic synthesis for its ability to form stable complexes with other organic compounds, facilitating various chemical reactions.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, N,N-Dimethyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethanamine is used as a key intermediate in the synthesis of various pharmaceutical compounds due to its reactivity and ability to form stable complexes.
Used in Agrochemical Industry:
N,N-Dimethyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethanamine is also utilized in the agrochemical industry for the synthesis of agrochemicals, where its reactivity and complex-forming ability contribute to the development of effective products.
Used as a Cross-linking Agent in Polymer Production:
In the polymer industry, N,N-Dimethyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethanamine is used as a cross-linking agent, enhancing the properties of polymers by forming stable connections between polymer chains.
Used as a Stabilizer in Coatings and Adhesives Formulation:
N,N-Dimethyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethanamine serves as a stabilizer in the formulation of coatings and adhesives, improving their performance and durability by forming stable complexes with other components in the formulation.

Upstream product

• 107-99-3 2-(dimethylamino)ethyl chloride 
• 269409-70-3 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol 
• 4584-46-7 (2-chloroethyl)dimethylamine hydrochloride 
• 2474-07-9 [2-(4-bromophenoxy)ethyl]dimethylamine 
• 73183-34-3 bis(pinacol)diborane 
• 108-01-0 2-(N,N-dimethylamino)ethanol 

Downstream Products

• 10540-29-1 tamoxifen 
• 13002-65-8 (E)-tamoxifen 

Relevant articles and documents

PYRROLO [2, 3-B] PYRIDINES OR PYRROLO [2, 3-B] PYRAZINES AS HPK1 INHIBITOR AND THE USE THEREOF

Disclosed herein is a compound of Formula (AIII) or (III), or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions comprising thereof. Also disclosed is a method of treating HPK1 related disorders or diseases by using the compound disclosed herein.

MAP4K4 INHIBITORS

This invention relates to pyrrolopyrimidine comprising compounds that may be useful as inhibitors of Mitogen-activated Protein Kinase Kinase Kinase Kinase-4 (MAP4K4). The invention also relates to the use of these pyrrolopyrimidine comprising compounds, f

PYRAZOLOPYRIMIDIN-2-YL DERIVATIVES AS JAK INHIBITORS

New pyrazolopyridmiin-2-yl derivatives are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS

Provided are pyridopyrazine compounds of formula (1), pharmaceutical compositions thereof and methods of use therefore, wherein R1, R2, R3, R4 and m are as defined in the specification.

SUBSTITUTED PYRIDOPYRAZINES AS NOVEL SYK INHIBITORS

Provided are certain pyridopyrazine compounds, pharmaceutical compositions thereof and methods of use therefor.

AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME

The invention relates to novel azacarbonlines having formula (I), wherein: R3, R4 represent independently H; hal; CF3; substituted oxy, optionally substituted alkoxy; optionally substituted amino; substituted carbonyl; optionally substituted carboxyl; optionally substituted amide; sulphur, such as optionally substituted sulphones, sulphoxides or sulphides; linear, branched or cyclic C1-C10 alkyl optionally comprising an optionally substituted heteroatom; optionally substituted linear, branched or cyclic C2-C7 alkenyl; optionally substituted linear or branched C2-C6 alkynyl; optionally substituted aryl or heteroaryl; of which may be optionally substituted; in the form of a base or an acid addition salt. The invention also relates to the use of same in therapeutics for the treatment of cancer and to synthesis methods.

KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME

The invention is directed to a compound represented by the following structural formula and pharmaceutically acceptable salts thereof: Compounds represented by this structural formula are kinase inhibitors and are therefore disclosed herein for the treatment of cancer. Definitions for the variables in the structural formula are provided herein.

PYRROLO[2,3-d]PYRIMIDINES THAT MODULATE ACK1 AND LCK ACTIVITY

Compounds that modulate the action of ACK1 and LCK, and related compositions methods for treating ACK1- and LCK-mediated diseases are described. In one aspect, the compounds have the general structure: where the values of the substituents are provided her

Furanopyridine derivatives and methods of use

The present invention relates to furanopyridine compounds having the general Formula I: and stereoisomers, tautomers, solvates, pharmaceutically acceptable salts and derivatives, and prodrugs thereof. The invention also includes pharmaceutical composition